- Price
- $28.35
- Day
- +9.42%
- Mkt Cap
- $2.92B
- 52W Range
- $15.60 – $38.26
- Volume
- 2.11M
- Beta
- 2.21
Find a company by name or ticker and open its page
Breaking news, press releases, and analyst updates.
Most recent articles and analysis covering this company.
Updated BEAM-302 Phase 1/2 Clinical Data Selected for Late-Breaking Oral Presentation at the European Respiratory Society (ERS) Congress 2026
Read full article
Beam Therapeutics Inc. (BEAM) came out with a quarterly loss of $1.18 per share versus the Zacks Consensus Estimate of a loss of $1. This compares to a loss of $1 per share a year ago.
Read full article
Beam Therapeutics offers compelling upside, with a $2.64B market cap and a promising gene-editing pipeline spanning hematology and liver-targeted diseases. Lead programs Risto-cel, BEAM-302, and BEAM-301 demonstrate superior or competitive efficacy and safety profiles versus key competitors, supporting significant commercial potential. BEAM's $1.2B liquidity provides a cash runway well into 2029, with additional revenue from collaborations, notably with Eli Lilly and Pfizer.
Read full article
Beam Therapeutics Inc. (NASDAQ: BEAM - Get Free Report) has received an average recommendation of "Moderate Buy" from the fourteen ratings firms that are presently covering the company, MarketBeat reports. One analyst has rated the stock with a sell rating, three have assigned a hold rating and ten have assigned a buy rating to the company.
Read full article
CAMBRIDGE, Mass., July 23, 2026 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that the company will present updated clinical data from the Phase 1/2 trial evaluating BEAM-302 for alpha-1 antitrypsin deficiency (AATD) at the European Respiratory Society (ERS) Congress 2026, taking place September 5–9, 2026, in Barcelona, Spain.
Read full article
Amova Asset Management Americas Inc. lowered its stake in Beam Therapeutics Inc. (NASDAQ: BEAM) by 13.2% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 3,825,585 shares of the company's stock after selling 583,715 shares during the quarter. Beam Therapeutics makes
Read full article
Beam Therapeutics' growing pipeline could reward patient investors.
Read full article